Vergelijking
Mazdutide vs. Retatrutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
2259884-03-0
2381089-83-2
Molecuulmassa
4790 g/mol
4731.6 g/mol
Halfwaardetijd
132 h
144 h
Sequentie
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSWerkingsmechanisme
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
5
waarvan bij mensen
4
4
Geregistreerde effecten
4
4
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
0
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Mazdutide and Retatrutide?
- Mazdutide is classified as "Metabool", while Retatrutide is classified as "Metabool". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Retatrutide?
- The highest available evidence level is "Humane RCT" for Mazdutide and "Humane RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Retatrutide in Germany and the United States?
- Duitsland: Mazdutide — Alleen onderzoek, Retatrutide — Niet goedgekeurd. Verenigde Staten: Mazdutide — Alleen onderzoek, Retatrutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.